With a FDA phase 3 trial succeeding, there is a partner there 100% if they wanted it.
Financially it would mean giving up future cash flows, so SI will need to figure out the best path forward for shareholders. Do another cap raise (at a reasonable price) before partnering CHF, lower back pain... or partner pediatric aGVHD resolve the short term cash problem but give away future cash flows.
This is a long term investment, irrational decisions now can have a significant detrimental effect to the long term value of MSB.
More importantly though, the technology is being validated in FDA phase 3 clinical trials. MSB’s MSC technology is no longer a “dream”, it is now becoming reality. 2018 milestone year.
NIH sponsored 2b CHF LVAD trial up next.
MSB trading, page-9
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |